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A B S T R A C T
Neuroendocrine tumors (NETs) constitute a heterogeneous group of tumors char-
acterized by the simultaneous expression of specific marker proteins and cell type-
specific hormonal products. Metaiodobenzyluanidine (MIBG), labelled with 131I or 
123I, and 111In-pentetreotide (octreoscan) are the radiopharmaceuticals of choice in 
current clinical practice. Positron emitting radiopharmaceuticals that are used in 
positron emission tomography (PET) imaging are 18F-fluorodeoxyglucose (18F-FDG), 
18F-fluorodopamine (18F-DOPA), 11C-hydroxy-tryptophan (11C-HTP), and Gallium-68 
(68Ga-DOTATATE or DOTATOC). For the diagnosis of gastroenteropancreatic neu-
roendocrine tumors (GEPs), octreoscan is the preferred imaging method because of 
its high sensitivity. The 131î123î-MIBG scintigraphy is useful to characterize and locate 
intra-adrenal (pheochromocytomas) and extra-adrenal paragangliomas. Octreoscan 
has also high accuracy for extra-adrenal paragangliomas. Also, 18F-FDG-PET or PET/
CT seems to be useful in detecting the pheochromocytomas and GEPs that fail to 
concentrate MIBG and octreocan. The 123I-MIBG scintigraphy combined with urine 
analysis of catecholamine metabolites is the most sensitive indicator of neuroblas-
toma. For the diagnosis of small cell lung cancer and pituitary adenomas, octreoscan 
has a high sensitivity. On the contrary, in medullary thyroid cancer the sensitivity of 
octreoscan and 131î/123î-MIBG is low but sensitivity of 18F-FDG PET or PET/CT and 
68Ga-DOTATATE and DOTATOC PET or PET/CT seems to be higher. With the 
introduction of 131I-MIBG and octreotide labelled with several radioisotopes, the field 
of treatment with radionuclides has been extended to a wide range of NETs. Firstly, 
111In-DTPA-octreotide was used in some clinical trials but recent advances in somato-
statin analogues have paved the way to the development of new radiopharmaceuticals 
labelled with 177Lu and 90Y radionuclides.
I N T R O D U C T I O N
Neuroendocrine tumors (NETs) constitute a heterogeneous group of tumors em-
bracing all neuronal and endocrine elements sharing a common phenotype, character-
ized by the simultaneous expression of specific marker proteins and cell type-specific 
hormonal products.1 Although estimates vary, the annual incidence of clinically signifi-
cant neuroendocrine tumors is approximately 2.5-5 per 100,000; two thirds are carcinoid 
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tumors and one third other NETs.2 The prevalence has been 
estimated as 35 per 100,000, and may be considerably higher 
if clinically silent tumors are included.2 The various kinds of 
cells that can give rise to NETs are present in endocrine glands 
and are also diffusely distributed throughout the body, most 
commonly Kulchitsky cells or similar enterochromaffin-like 
cells, that are relatively more common in the gastrointestinal 
(56%) and pulmonary systems (12%).3
Neuroendocrine tumors can range from benign lesions 
to highly aggressive cancers. On the basis of their anatomical 
and clinical features, NETs can be classified into different 
types (Table 1).1,4 Diagnosis of NETs has represented a major 
challenge in the past decades mostly because of their slow 
metabolism and for the fact that they often present as small 
lesions with variable anatomical localization.5 They also pose 
significant challenges because of the heterogeneous biology 
of the tumors. Structural imaging techniques have suboptimal 
sensitivity in most published series and diagnosis is often de-
layed until metastatic disease is present. Current guidelines 
emphasize the importance of functional imaging for evaluating 
the extent of NETs.6
Metaiodobenzyluanidine (MIBG), labeled with 131I or 
123I, and DTPA-D-Phe-octreotide, labeled with 111In, are the 
radiopharmaceuticals of choice in current clinical practice.7 
Also, positron emitting radiopharmaceuticals are used, like 
18F-fluorodeoxyglucose (18F-FDG), 18F-fluorodopamine (18F-
DOPA), 11C-hydroxy-tryptophan 11C- (HTP), and Gallium-68 
(68Ga-DOTATATE or DOTATOC).8 New radiopharmaceu-
ticals based on somatostatin analogues are under investiga-
tion.7,9 Radiolabelled monoclonal antibodies (anti-CEA and 
anti-chromogranin-A) can be considered either of historical 
or experimental value and the use of 99mTc(V)-DMSA is going 
to be abandoned.7 In this review we present the radiopharma-
ceuticals that are used in diagnosis and therapy of the most 
frequent types of NETs (Table 2). 
A .  R A D I O P H A R M A C E U T I C A L S
A 1 .  I M A G I N G
1.1 Octreoscan
Somatostatin is a regulatory peptide widely distributed in 
the human body. In the nervous system somatostatin acts as a 
neurotransmitter, whereas its hormonal activities include the 
inhibition of the physiologic and tumorous release of growth 
hormone, insuline, glucagone, gastrin, serotonin, and calcito-
nin.10 Its other actions comprise an antiproliferative effect on 
tumors and also specific regulation of immune responses.10 
Somatostatin action is mediated through membrane-bound 
receptors, of which five have been cloned (sst1-sst5).11 They 
all belong to the family of G-protein-coupled receptors. 
Somatostatin is a peptide with two forms, containing 14 and 
28 amino acids, respectively.6 Both bind to all subclasses of 
somatostatin receptors but are rapidly degraded in the blood 
by peptidases and have a short half life (ø1/2=1-2 min).6 
Various synthetic somatostatin analogues have been made to 
increase resistance to peptidases and thereby allow systemic 
TABLE 1. Classification of neuroendocrine tumors
Types of neuroendocrine tumors
 Neuroendocrine tumors of the gastro-entero-pancreatic (GEP) 
tract: pancreatic endocrine tumors and neuroendocrine tumor 
of the stomach, duodenum, jejunum, appendix and caecum, 
colon and rectum
 Tumors of sympatho-adrenal lineage: pheochromocytomas, 
paragangliomas, neuroblastomas
 Medullary carcinoma of the thyroid gland (MTC)
 Neuroendocrine tumors of the lung: pulmonary carcinoid 
tumors, small-cell lung cancer (SCLC) and large-cell 
neuroendocrine carcinoma (LCNEC of the lung)
 Neuroendocrine tumors of the anterior pituitary
 Several inherited conditions: multiple endocrine 
neoplasia type 1 (MEN1), multiple endocrine neoplasia 
type 2 (MEN2) von Hippel-Lindau (VHL) disease, 
neurofibromatosis type 1, tuberous sclerosis, Carney 
complex
 Merkel cell carcinoma of the skin 
 Parathyroid tumors
TABLE 2. Radiopharmaceuticals of choice for neuroendo-
crine tumor imaging in current clinical practice
Radiopharmaceutical labelled with a radionuclide that 
emits Ć radiation
Metaiodobenzyluanidine (MIBG), labelled with 131I or 123I 
111In-pentetreotide (Octreoscan) 
99mTc-Depreotide (Neospect) 
99mTc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotide)
Radiopharmaceutical labelled with a positron-emitting 
radionuclide  ą + )
18F-fluorodeoxyglucose (18F-FDG)
18F-fluorodopamine (18F-DOPA)
11C-hydroxy-tryptophan (11C-HTP)
68Ga-DOTATATE or DOTATOC).
Treatment with radiolabelled somatostatin analogues
[111In-DTPA0]octreotide
[90Y-DOTA0, Tyr3]octreotide
[177Lu-DOTA0,Tyr3] octreotate
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delivery by virtue of longer circulation times. These synthetic 
somatostatin analogues have varying affinity for the different 
types of somatostatin receptors.6 However, only sst2, sst5 and, 
to some extent, sst3 have a high affinity for the commercially 
available synthetic peptides, octreotide, lanreotide and va-
preotide.10 The most widely used is an 8-amino acid peptide, 
octreotide, with half life T1/2= 2,83 days.11 This peptide has 
been radiolabelled as [111In] diethylenetriaminepentaacetic 
acid (DTPA)-octreotide (Octreoscan, Covidien, Petten, The 
Netherlands).12 It has highest affinity for sstr2 and is suitable 
for imaging on a gamma camera.6
Somatostatin receptors have been identified in vitro in 
a large number of human neoplasias. A high incidence and 
density of somatostatin receptors is found in neuroendocrine 
tumors, such as pituitary adenoma, pancreatic islet cell tumor, 
carcinoid, pheochromocytoma, paraganglioma, medullary 
thyroid cancer, and small cell lung carcinoma.12 Tumors of 
the nervous system including meningioma, neuroblastoma, 
and medulloblastoma also express very often a high density 
of somatostatin receptors. But also tumors not known to be 
classically originating from endocrine or neural cells, such as 
lymphoma, breast cancer, renal cell cancer, hepatocellular can-
cer, prostate cancer, sarcoma, and gastric cancer, can express 
somatostatin receptors. In the majority of these tumors, the 
somatostatin receptor subtype-2 is predominantly expressed, 
although low amounts of other somatostatin receptor subtypes 
may be concomitantly present.13 It should be emphasized 
that selected non-tumoral lesions may express somatostatin 
receptors, like active granulomas in sarcoidosis and inflamed 
joints in active rheumatoid arthritis.10 The expression of 
somatostatin receptors is therefore not specific for tumoral 
pathologies. Common indications for [111In-DTPA0] octreotide 
scintigraphy include the detection and localization of a variety 
of neuroendocrine and other tumors and their metastases, the 
staging of patients with neuroendocrine tumors, the follow-
up of patients with known disease, and lastly the selection of 
patients with inoperable and/or metastatic tumors for peptide 
receptor radionuclide therapy.
Several attempts have been performed in order to label 
somatostatin analogues with 99mTc, which is the most available 
radionuclide. Thus, 99mTc-EDDA/HYNIC-Tyr3-Octreotide 
(Tektrotide) scintigraphy seems to have significant sensitivity 
and specificity in GEPs and medullary thyroid cancer (MTC).14 
Also, 99mTc-Depreotide (Neospect) is another commercially 
available somatostatin analogue that has been approved 
specifically for the detection of lung cancer in patients with 
pulmonary nodules.15
1.2 MIBG
Metaiodobenzyluanidine (MIBG) is a derivative of 
guanethidine and acts as an analogue of norepinephrine.1 It 
exploits the type 1 uptake mechanism at the cell membrane, 
and is stored within intracellular storage vesicles. 1 Cellular 
uptake of MIBG is driven by passive diffusion, or active uptake, 
and the compound, carried by norepinephrine transporters 
facilitated by vesicular monoamine transporters, is deposited 
in intracellular storage granules.1 Today, 131I-MIBG and 123I-
MIBG are both available for diagnostic purposes. Physical 
considerations - 159KeV photon energy, T1/2=13.2h, fewer 
particulate emissions which lead to favorable dosimetry - and 
clinical experience indicate that the 123I-labeled agent is a supe-
rior radiopharmaceutical, better suited to gamma cameras and 
intraoperative detection of tumors.16 It allows better quality 
images, better photon detection and greater sensitivity. The 
higher photon flow allows high-quality single-photon emission 
computed tomography (SPECT) to be carried out, which may 
be an advantage.17 Nevertheless, because of its lower cost and 
easier availability, 131I-MIBG is still used for routine applica-
tions.16 Also, 125I-MIBG is available for in vitro experiments and 
biodistribution studies in animals but it is reserved.16
Metaiodobenzyluanidine (MIBG) is concentrated in 
sympatho-adrenergic tissues, especially the chromaffin tis-
sue of the adrenal medulla.1 It localizes to adrenomedullary 
tumors, hyperplastic adrenal medulla and the healthy adrenal 
medulla; in addition, carcinoid tumors and MTC can also 
accumulate MIBG18. The efficiency of 123I-MIBG is excellent 
for the visualization of intra-adrenal (pheochromocytomas) 
and extra-adrenal (paragangliomas) chromaffin cell tumors, 
and can identify multiple tumors in patients with familial 
syndromes, showing a diagnostic sensitivity and specificity of 
about 90%.18
1.3 Positron-emitting radiopharmaceuticals for PET 
imaging
Positron emission tomography (PET) utilizes the ability of 
radiolabelled tracers to be taken-up by certain tumours, and 
thus selectively assesses the function of different metabolic 
pathways of the specific tissue.18 Positron-emitting isotopes 
frequently used for PET imaging include oxygen-15 (15O), 
nitrogen-13 (13N), carbon-11 (11C), and fluorine-18 (18F). 
Somatostatin analogues labelled with positron-emitting 
radionuclides are used for imaging with PET cameras or hybrid 
PET/CT cameras with great potential because of two advan-
tages that they have over Ć-emitting analogues. First, many of 
them have a better affinity for the somatostatin receptor sub-
type-2, which is most commonly expressed by neuroendocrine 
tumors. Second, the better spatial resolution of PET imaging 
and the combined anatomical and functional information that 
obtained with the hybrid PET/CT technique, result in a higher 
sensitivity of this type of scanning.12 The positron-emitting ra-
diopharmaceuticals currently available for neuroendocrine tu-
mor imaging may be divided into two grours: tracers that mark 
cell metabolism – [18F]FDG (fluorodeoxyglucose), [18F]DOPA 
(fluorodopamine), [11C]HTP ([11C]5-hydroxytryptophan), and 
tracers being specific ligands for receptors expressed on these 
cells- [68Ga]DOTA-peptides like [68Ga]DOTA-TOC and [68Ga]
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DOTA-TATE, bombesin, vasoactive intestinal peptide-VIP, 
cholecystokinin-CCK receptor family, glucagone-like peptide.5 
18F-fluorodeoxyglucose (18F-FDG) was the first tracer used, 
reflecting the increased glucose uptake in malignant tumors.8, 
18 During the past few years, numerous studies have demon-
strated that the uptake of 18F-FDG relates to tumor grade and 
proliferation status in a wide variety of tumors.5 In general, 
low-grade, slowly proliferating tumors take up less 18F-FDG 
than poorly differentiated, rapidly growing tumors.5 18F-FDG, 
the most commonly used tracer for PET oncological studies, 
is certainly not the tracer of choice to study well differentiated 
neuroendocrine tumors.5 The metabolic pathway synthesizing 
5-hydroxytryptamine (5-HT) from 5-hydroxytryptophan (5-
HTP) occurs in carcinoids and other NETs and can thus also 
be used for PET-imaging; 11C-5-HTP is specifically trapped by 
serotonin producing tumors and this can be further enhanced 
by the concomitant administration of carbidopa.18 
A 2 .  R A D I O N U C L I D E  T H E R A P Y
Coupling a radioisotope to a molecule which would specifi-
cally bind to tumor cells could deliver an effective radiation 
dose to the tumor without damage to non-tumor tissues.19 
Tumor heterogeneity may cause incomplete responses unless 
the radiation delivered can kill the nearby tumor cells that 
are target-negative; this depends on the cross-fire from the 
radioisotope localized in or on the target-positive tumor cells.18
Increasing understanding of tumor biology at the molecu-
lar level has led to the advent of molecular biological agents 
for use in cancer therapy, allowing targeted treatment of 
solid tumors based on information about alterations in cel-
lular pathways and the cell cycle genomics, proteomics and 
epigenetics.20 With the introduction of 131I-MIBG and, more 
recently, octreotide labelled with several radioisotopes, the 
field of treatment with radionuclides has been extended to a 
wide range of NETs.18, 21 
Peptide receptor radionuclide therapy (PRRT) with radi-
olabelled somatostatin analogues has become an established 
method of treatment of disseminated NETs.22 Peptides used 
for PRRT need to be designed for high tumor retention. The 
ą-emitters that are suited for therapeutic use and the most 
frequently used are 90Y-Yttrium (ąmax=2.3ñeV, T1/2=64h) 
and 177Lu-Lutetium (ąmax=0.5ñeV, T1/2=161h), bound to 
octreotide analogues.23 As high energy ą radiation has a long 
penetration range in tissue, it is less efficient when treating 
small tumor lesions (<1-2 g), as much of the energy is depos-
ited outside the lesion. Therefore, high energy particles, such as 
90Y, have been considered more appropriate for the treatment 
of larger tumors, whereas low energy particles, such as 177Lu, 
may be more suitable for the treatment of small lesions.23 Apart 
from ą-emitters, the auger-emitter 111In has also been used.
Firstly, 111In-DTPA-octreotide was used in some clinical 
trials but recent advances in somatostatin analogues have 
paved the way to the development of new analogues, which 
can be labelled with both 177Lu and 90Y radionuclides and is 
characterized by a higher affinity for somatostatin receptor 
type 2 leading to high tumor uptake.20, 22 Several studies, most 
of them phase II clinical trials, have been published examining 
the activity of biologically targeted agents in NETs, and some 
have shown encouraging results with favourable rates of partial 
responses or stable disease.24-26
Dose-limiting renal toxicity is probably the most important 
issue in toxicity of PRRT.23 Positively charged amino acids but 
also plasma-expanders have been used successfully to reduce 
kidney re-absorption of radiolabelled octreotide analogues.23 
Acute hematological toxicity is usually mild, no matter which 
of the radionuclide is used. Liver toxicity may occur in single 
patients with liver metastases undergoing PRRT.23
B .  N E U R O E N D O C R I N E  T U M O R S
B 1 .  G A S T R O E N T E R O PA N C R E A T I C 
N E U R O E N D O C R I N E  T U M O R S  ( G E P )
Gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) are a poorly understood group of lesions that encom-
pass a broad category of neoplasms derived from neuroendo-
crine cells of the gastrointestinal mucosa and the pancreas.27 
The lesions are grouped based on the acceptance that they 
have a common cell lineage and produce similar secretory 
products: chromogranin A, synaptophysin, and neuron-specific 
enolase. The GEP-NET classification includes carcinoids and 
pancreatic endocrine tumors: insulinomas, gastrinomas, tu-
mors secreting vasoactive intestinal peptide (VIPomas), gluca-
gonomas, somatostatinomas, and non-functional pancreatic 
NETs. Although they are more rare than adenocarcinomas, 
the estimated incidence of pancreatic endocrine tumors is 
about 5 per 1,000,000 population, whereas carcinoids (bron-
chopulmonary and gastrointestinal) comprise about 0.46% 
of all malignancies.28 Although they are categorized together, 
their clinical behaviour is strikingly divergent in terms of both 
symptoms and outcome. Thus, the overall 5-year survival rate 
for all carcinoids is 67.2%, whereas the overall 5-year survival 
rate for pancreatic endocrine tumors varies from 97% (benign 
insulinomas) to about 30% in non-functional ones.28, 29
The radiolabeled somatostatin analogue, octreotide, can 
be imaged by a nuclear medicine gamma camera and used to 
detect primary and metastatic NETs.20 This modality allows 
for total body scanning and has high sensitivity - 61% to 100% 
- depending on tumor subtype. Positive scintigraphy has been 
associated with expression of the somatostatin receptor sub-
type 2 and improved overall survival.30 The addition of single 
photon emission computed tomography (SPECT) allows for 
increased anatomic detail to the functional information gained 
with nuclear imaging.20
The overall results from the literature indicate that oc-
treoscan scintigraphy is particularly useful for small bowel 
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carcinoids, which may be difficult to localize by conventional 
methods.7, 31 Reported values for the detection of known car-
cinoid tumor localizations vary from 80% to nearly 100%.10 
Also, the detection of unexpected tumor sites, not suspected 
with conventional imaging, is reported by several investiga-
tors.7 More lesions can be visualized with SPECT imaging than 
planar imaging, so it is mandatory for an accurate evaluation. 
Imaging of carcinoids is independent of tumor site or hormonal 
secretion; moreover, distant metastases may be detected by 
whole body scanning.7 Due to its high sensitivity, somatostatin 
receptor imaging can be particularly useful in localizing the 
tumor site when surgery is planned.32
According to the reported data, the sensitivity of octre-
oscan in endocrine pancreatic tumors varies from 70% to 
90%.7 In patients with gastrinomas the sensitivity is about 90% 
and studies have shown that the results of this method altered 
patient management in 47% (Fig. 1).10 Octreoscan also shows 
high accuracy in detecting VIPomas and glucagonomas, with 
a sensitivity of about 75%-85%.7 However, the sensitivity of 
the method for the detection of insulinomas is generally lower 
(50%-69%) due to a smaller number of somatostatin receptors 
that bind to pentetreotide.7, 10
Thus, the impact of octreoscan on patient management 
is fourfold:10 1. It may detect respectable GEP that would be 
unrecognized with conventional imaging techniques, 2. It may 
prevent surgery in patients whose tumors have metastasized 
to a greater extent than can be detected with conventional 
imaging, 3. It may direct the choice of therapy in patients with 
inoperable tumors, and 4. It may be used to select patients for 
peptide receptor radionuclide therapy.
Neospect (99mTc-depreotide) is another commercially 
available somatostatin analogue but because of the relatively 
high abdominal background and the impossibility to perform 
delayed imaging due to the short half-life of the tracer, it is 
less suited for the detection of abdominal neuroendocrine 
tumors.9 Tektrotide (99mTc-EDDA/HYNIC-Tyr3-Octreotide) 
has important features in common with octreoscan. Moreover, 
tektrotide has advantages deriving from the optimal physical 
characteristics of 99mTc, with improved scintigraphic image 
quality, easier availability and much lower cost.14 On the other 
hand, there is general agreement that 123I/131I-MIBG has only 
a complementary role to play in the diagnosis of GEP tumors 
and may occasionally detect lesions that are not visualized with 
somatostatin receptor scintigraphy.7
Although 18F-FDG has been successfully and widely em-
ployed in oncology, its uptake is not high in well differentiated 
neuroendocrine lesions.34 The majority of NETs that express 
somatostatin receptors are well differentiated and therefore 
the role of 18F-FDG PET in these cases is limited.35 Increased 
18F-FDG uptake can be seen in less-differentiated NETs 
without somatostatin receptors; in such cases the sensitivity 
of 18F-FDG PET is clearly higher than that of scintigraphy 
with octreoscan.8,34 Since scintigraphy with octreoscan fails to 
visualize 10–20% of GEP tumors, 18F-FDG PET may prove to 
be useful in certain cases, although this needs to be formally 
assessed by a prospective trial.36 Other positron emitter trac-
ers seem to be more promising.34 The 5-hydroxytryptophan 
(5-HTP) labelled with 11C has shown an increased uptake in 
carcinoids. Imaging with 11C-5-HTP PET has been shown to 
be superior to CT scanning in diagnosing GEP tumors and 
monitoring their response to therapy.8 Another PET radiop-
harmaceutical, 11C-L-DOPA, seems to be useful in visualizing 
endocrine pancreatic tumors.34 
Mapping of the presence of various peptide receptors on 
the cell membrane by peptide receptor scintigraphy has be-
come an evolving procedure which is non-invasive and without 
major side-effects, and an easy-to-perform method in the 
selection of patients for therapy with radionuclides.37 Treat-
ment with radiolabelled somatostatin analogues (PRRT) is a 
promising new tool in the management of patients with inoper-
able or metastasized neuroendocrine tumors.12 Symptomatic 
improvement may occur with all 111In-, 90Y-, or 177Lu-labeled 
somatostatin analogues that have been used for PRRT.12,25,38
As at that time no other chelated somatostatin analogues 
labelled with ą-emitting radionuclides were available, early 
studies in the mid- to late 1990s used [111In DTPA0] octreotide 
for PRRT. Initial studies with high dosages of [111In-DTPA0] 
octreotide in patients with metastasized neuroendocrine 
tumors were encouraging with regard to symptom relief, but 
FIGURE 1. Octreoscan images in a 65-year-old man with known 
pancreatic endocrine tumor (gastrinoma), about 4 years after the 
initial surgical treatment. Images show recurrence of the disease, 
with pathological uptake in multiple hepatic lesions 
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partial remissions were exceptional.39,40 The next generation 
of somatostatin receptor-mediated radionuclide therapy used 
a modified somatostatin analogue, [Tyr3]octreotide, with a 
higher affinity for the somatostatin receptor subtype-2, and a 
different chelator, DOTA instead of DTPA, in order to ensure 
a more stable binding of the intended ą-emitting radionuclide 
Yttrium-90 (90Y). Despite differences in protocols used, com-
plete plus partial responses in most of the different studies with 
[90Y-DOTA0, Tyr3]octreotide are in the same range, in between 
10% and 30%, and therefore better than those obtained 
with [111In-DTPA0]octreotide.39,41 The [177Lu-DOTA0,Tyr3] 
octreotate potentially represents an important improvement 
because of the higher absorbed doses that can be achieved 
to most tumors with about equal doses to potentially dose-
limiting organs and because of the lower tissue penetration 
range of 177Lu if compared with 90Y, which may be especially 
important for small tumors. Overall, objective tumor response 
rate was 46%.25 It seems that the results that were obtained 
with [90Y-DOTA0,Tyr3]octreotide and [177Lu-DOTA0,Tyr3] 
octreotate are very encouraging in terms of tumor regression. 
Also, if kidney protective agents are used, the side effects of 
this therapy are few and mild, and the median duration of the 
therapy response for these radiopharmaceuticals is 30 and 40 
months, respectively.12
B 2 .  P H E O C H R O M O C Y T O M A - PA R A G A N G L I O M A
The most widely used radiopharmaceutical for the diag-
nosis of pheochromocytomas is MIBG radiolabelled with 123I 
and 131I.7 It is useful to characterize and locate intra-adrenal 
(pheochromocytomas) and extra-adrenal paragangliomas, it 
can determine the extent of disease and allows the diagnosis 
of relapses during postoperative follow-up. Worldwide ex-
perience has proved the ability of 131I-MIBG scintigraphy to 
locate sporadic pheochromocytoma, paragangliomas, chemo-
dectomas and malignant metastatic disease, as well as various 
familial syndromes associated with pheochromocytomas, 
including MEN2A and 2B, von Hippel-Lindau syndrome, 
von Recklinghausen’s neurofibromatosis, and simple familial 
pheochromocytomas.16 Even non-functional paragangliomas 
may be visualized, as reported by several authors.16 The overall 
diagnostic sensitivity of 131I-MIBG imaging when evaluating 
the combined data reported in major series is approximately 
86%.7,16,42,43 In malignant pheochromocytomas the sensitivity 
is higher, 92.4%.16 Sensitivity improves still further with 123I-
MIBG.16 In fact, 123I-MIBG can visualize a number (~8%) of 
low MIBG-concentrating pheochromocytomas which cannot 
be visualized with 131I-MIBG uptake.16 Radiolabelled MIBG 
imaging is highly specific as it gives very few (1%-5%) false-
positive results and has a high tissue specificity, which permits 
the nature of the mass to be elucidated.16
The sensitivity of octreoscan for pheochromocytoma 
detection seems to be comparable to that of MIBG but the 
results depend also on the tumor site, as it is well known that 
adrenal lesions are difficult to visualize with octreoscan due to 
its high renal activity.7 Concerning the paragangliomas, there 
is clinical evidence that the sensitivity of octreoscan, especially 
for head and neck paragangliomas, is superior to that of any 
other nuclear medicine test or radiological procedure, even 
if MIBG imaging has very good specificity.7,44 The accuracy 
of octreoscan is 90%, the sensitivity 94% and the specificity 
75%.7 In fact reports seem to indicate a higher sensitivity of 
octreoscan in detecting metastatic disease than in localizing 
benign tumors and in those tumors producing dopamine when 
MIBG is lacking sensitivity.7
Most pheochromocytomas accumulate 18F-FDG and up-
take is found in a greater percentage of malignant than benign 
tumors.7 These data suggest that 18F-FDG PET can be useful 
in detecting the pheochromocytomas that fail to concentrate 
MIBG. A comparison between 18F-DOPA PET and MIBG 
scintigraphy in the same series of patients showed that the sen-
sitivity of PET was 100% versus 71% for MIBG scintigraphy; 
both modalities had 100% specificity.45 Paragangliomas also 
show marked uptake and retention of 18F-FDG.7
Other PET radiopharmaceuticals, such as [18F]FDA, [18F]
DOPA, [11C]epinephrine, and [11C]hydroxyephedrine have all 
been demonstrated to image pheochromocytomas and related 
neoplasms.8,41,42
Examinations with MIBG can also be used to select pa-
tients for subsequent radiometabolic therapy on the basis of 
MIBG uptake by the cancer cells.7 Before using 131I-MIBG 
therapy, a diagnostic 123I-MIBG scan is necessary to substan-
tiate the avidity of tumor cells for the radionuclides.18 The 
cumulative reported response to 131I-MIBG therapy in patients 
with phaeochromocytomas and paragangliomas has been 
extensively reviewed.46 In the majority of patients clinically 
symptomatic improvement relating to catecholamine hyper-
secretion was observed; a biochemical response was almost 
always associated with a symptomatic response. An overall 
tumor response (partial tumor response or stabilization of the 
disease) was obtained in 58% of the patients.46,47 The reported 
response to 131I-MIBG therapy is quite heterogeneous, as it 
depends on several factors including tumor size and extension, 
131I-MIBG tumor uptake and retention.46
B 3 .  N E U R O B L A S T O M A
Neuroblastoma is almost exclusively a pediatric neoplasm 
and the most common extracranial solid tumor in children, 
accounting for 8%-10% of all childhood cancers.48 Being a 
tumor of the neuroblasts of the sympathetic nervous system, 
the adrenal cells are the commonest site of origin (greater than 
50%) followed by other retroperitoneal sites, mediastinum, 
pelvis and neck. 
For neuroblastoma there is a general preference for 
123I-MIBG and due to favorable dosimetry and superior im-
age quality the 123I-MIBG scintigraphy combined with urine 
analysis of catecholamine metabolites is the most sensitive in-
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dicator of neuroblastoma.7, 16 Whole-body MIBG scintigraphy, 
including the limbs and skull as frequent sites for metastases, 
depicts primary and residual/recurrent neuroblastomas, as 
well as lesions in bone, soft tissue and bone marrow. It has 
high sensitivity (93%) and specificity (100%) for the diagnosis 
of neuroblastomas.49,50 Addition of SPECT and CT to MIBG 
scintigraphy can increase the accuracy of both methods.50 The 
concordance of 123I/131I-MIBG and octreoscan is about 85%, 
but there have been patients with only positive MIBG scans.7
Most neuroblastomas accumulate 18F-FDG and so 18F-
FDG uptake can be shown in neuroblastomas that fail to 
accumulate MIBG, as the concentration of FDG is not de-
pendent on type 1 catecholamine uptake.7,51 In patients where 
123I/131I-MIBG uptake is not seen, PET using 18F-FDG or other 
radiopharmaceuticals, might be indicated.46,51,52
Therapy with 131I-MIBG is most commonly used in the 
treatment of neuroblastoma.53 It was initially reserved for 
palliation of patients with recurrent disease. However, clini-
cal trials evaluating the role of 131I- MIBG as a first line drug, 
either as a single agent, or in combination with chemotherapy 
or myeloablation treatment, have been performed with mixed 
results and significant potential side effects. The response 
rates varied between 20% and 60% in newly diagnosed and 
relapsed or refractory patients.54 Despite all this information, 
the precise role of 131I-MIBG in the overall therapeutic strategy 
of neuroblastoma is far from being defined.
B 4 .  L U N G  T U M O R S
Somatostatin receptors may be expressed by lung tumors, 
particularly small cell lung cancer (SCLC) and bronchial 
carcinoid disease.55 Octreoscan may have a role to play in the 
localization and staging of bronchial carcinoid tumors both 
before and following treatment, and in detecting relapsed 
disease. Also, octreoscan has high sensitivity in the detec-
tion of primary SCLC but the sensitivity is greatly reduced in 
the detection of metastases.7 In a recent study, staging with 
octreoscan successfully located the primary tumor site with a 
sensitivity of 92%.56 Although detection of mediastinal lymph 
node dissemination was also relatively high (83%), octreoscan 
failed to detect most of the metastatic lesions outside the tho-
rax (25%), while its sensitivity for the detection of malignant 
lesions in the liver, adrenals, and bones, was 56%, 33% and 
17%, respectively.56
Various clinical studies have demonstrated the great ef-
fectiveness of 18F-FDG PET or PET/CT for disease staging, 
detection of persistent or recurrent disease, and evaluation 
of focal opacities.7 In SCLC, 18F-FDG PET or PET/CT can 
be considered a valid option for preoperative staging and 
subsequent treatment monitoring.57 It is an important tool in 
the staging work-up of SCLC if performed initially to allow 
rapid identification of patients with extensive disease, thereby 
sparing the patient additional radiological or invasive examina-
tions.58,59 Furthermore, the available clinical data suggest that 
18F-FDG PET or PET/CT can provide the basis for determin-
ing which treatment modality would be most appropriate dur-
ing the early stages of SCLC, when surgery is still an option, 
and that it is a useful tool to assess the response to therapy in 
treated patients.60
The potential role of radiolabelled somatostatin analogues 
as radiotherapeutic agents in the management of lung cancer 
is currently being explored.55 Somatostatin analogue therapy 
results in significant growth inhibition of both somatostatin 
receptor-positive and somatostatin receptor-negative lung 
tumors in vivo. Recent work indicates that these agents may 
enhance the efficacy of chemotherapeutic agents in the treat-
ment of solid tumors including lung cancer.55
B 5 .  M E D U L L A R Y  T H Y R O I D  C A N C E R
Medullary thyroid cancer (MTC) is rare, accounting for 
5%-10% of all thyroid malignancies. It may occur in either 
sporadic (75%-80%) or hereditary forms (20%-25% of cases).61 
More than 50% of thyroidectomized patients are not cured 
after surgery, as there is a persistent elevation of basal serum 
calcitonin levels, which implies residual tumor. There is no 
single sensitive diagnostic imaging method to reveal all MTC 
recurrences. Conventional morphologic imaging methods 
(ultrasound, CT, MRI) frequently fail to reveal the lesions 
because, after thyroidectomy has been performed, reliable 
differentiation between scar tissue and recurrent tumor is 
frequently not possible.61 The sensitivity of 123î/131î-MIBG 
was found to be only 31%.62 In the literature the sensitivity of 
octreoscan has been reported to be between 37% and 71%.61 
It seems that 18F-FDG öêø or PET/CT can play a major role 
in the follow-up of patients with postoperative elevated plasma 
calcitonin and the sensitivity for recurrence and residual dis-
ease detection per patient are reported to be 47.4%-85% (Fig. 
2).61,63,64 18F-FDG PET also provides additional information in 
a significant fraction of cases (up to 54%).65 Preliminary data 
suggest that the use of other PET tracers, such as 18F-DOPA 
and 68Ga-DOTATOC or 68Ga-DOTATATE, may provide a 
better lesion detection rate than does 18F-FDG.66 
B 6 .  P I T U I T A R Y  T U M O R S
Octreoscan in combination with other imaging modali-
ties is a useful tool in the diagnosis and follow-up of pituitary 
tumours.67 This method allows scar tissue to be differentiated 
from tumor recurrence after the surgical treatment of pitui-
tary adenomas.70 Somatostatin receptors were demonstrated 
in vitro in pituitary adenomas producing growth hormone or 
thyroid stimulating hormone.7,10 Also, in vivo, octreoscan is 
positive in most cases, but other pituitary lesions, as pituitary 
metastases from somatostatine-receptor-positive neoplasms, 
parasellar meningiomas, lymphoma, or granulomatous dis-
eases of the pituitary may give positive results. Therefore, the 
diagnostic value of octreoscan in pituitary tumors is limited.7 
It identifies patients with presence of positive receptors for 
88
HOSPITAL CHRONICLES 7(2), 2012
somatostatin, who can then be selected for medical treatment 
with analogues of somatostatin.67 Also, pituitary micro- and 
macro-adenomas may present as hypermetabolic foci on 18F-
FDG PET scan.68 
C O N C L U S I O N
Nuclear Medicine offers functional imaging for evaluat-
ing the extent of the heterogeneous group of neuroendocrine 
tumors (NETs). Metaiodobenzyluanidine (MIBG), labelled 
with 131I or 123I, and octreoscan are the radiopharmaceuticals 
of choice in the current clinical practice. In PET imaging, 
[18F]FDG may not be the ideal radiotracer for imaging these 
tumors. Preliminary data suggest that the use of other PET 
tracers, such as 18F-DOPA (18F-dihydroxyphenylalanine) and 
68Ga-DOTATOC or 68Ga-DOTATATE, may provide a better 
lesion detection rate. This suggestion needs to be confirmed 
in larger patient populations. For tumors that demonstrate 
uptake to a diagnostic scan with 123I- MIBG or octreoscan, 
therapy with 131I-MIBG or somatostatin analogues radiola-
belled with 111In-DTPA, 177Lu or 90Y radionuclides presents 
a further evolving therapeutic modality. Further data are 
needed to better acknowledge the role of the integrated use 
of metabolic and receptor targeted tracers in order to acquire 
more detailed information regarding the lesion biology and 
to identify the extent that this could be used to provide the 
patient with more tailored treatment options.
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